Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefotaxime + Netilmicin
- Development stage
- Unknown
- Lead developer
- Hoechst
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
The combination of cefotaxime and netilmicin is an antibiotic combination therapy used primarily for treating serious bacterial infections. Cefotaxime is a third-generation cephalosporin with broad-spectrum activity against Gram-positive and Gram-negative bacteria. Netilmicin is a semisynthetic aminoglycoside antibiotic. This combination demonstrates synergistic bactericidal effects against various pathogens, including resistant isolates of Serratia.
02
Targets
Bacterial RibosomePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on Cefotaxime + Netilmicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cefotaxime + Netilmicin.